Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
SAGE Therapeutics (SAGE) Stock Price & Analysis
773 Followers
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.36 - $49.56
Previous Close$41.78
Volume345.93K
Average Volume (3M)513.33K
Market Cap
$2.59B
Enterprise Value$2.59B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-4.7
Beta1.04
Next Earnings
May 04, 2023EPS Estimate
-$2.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.98
Shares Outstanding59,717,608
10 Day Avg. Volume465,407
30 Day Avg. Volume513,329
Standard Deviation0.16
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.05
Price to Sales (P/S)324.57
Price to Cash Flow (P/CF)2.90
P/FCF Ratio-5.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue537.24
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.60
Forecast
1Y Price Target
$56.58Price Target Upside29.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
SAGE Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $27.36 and its highest was $49.56 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is May 04, 2023 which is in 35 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Feb 16, 2023. The company reported -$2.47 earnings per share for the quarter, missing the consensus estimate of -$2.377 by -$0.093.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$2.52.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 59,717,610 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$2.47 in its last earnings report, missing expectations of -$2.377. Following the earnings report the stock price went down -0.111%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 17M.
---
SAGE Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$56.58 (29.36% Upside)
$56.58 (29.36% Upside)
Blogger Sentiment
Bearish
SAGE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 19.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $79.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.93%
12-Months-Change
Fundamentals
Return on Equity
-35.74%
Trailing 12-Months
Asset Growth
-25.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding SAGE
Simplify Propel Opportunities ETF
$2.15M
Fidelity Nasdaq Composite Index ETF
$809.43K
Up to five ETFs with an Outperform Smart Score that hold SAGE. The ETFs are listed according to market value of SAGE within the ETF
---
---